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Abstract
Pseudoaneurysms of the hepatic artery are a rare complication in patients with primary or
secondary liver tumors treated with intra-arterial chemotherapy. We present two patients who
developed this complication after placement of a catheter system into the gastroduodenal artery
and initiation of regional chemotherapy with floxuridine. Diagnosis was made after symptomatic
bleeding occurred, necessitating emergency angiography with coil embolization. Pseudoaneurysms
usually occur after mechanical damage of the vessel wall, but the chemical toxicity of floxuridine
may add to the development of vascular impairment.
Background
Hepatic artery chemotherapy (HAC) was developed in the
early 1960s to treat large, unresectable primary and sec-
ondary liver tumors [1,2]. This approach is based on the
rationale that local therapy through the hepatic artery
increases the exposure of the liver tumors to cytotoxic
agents, leading to higher response rates while limiting sys-
temic side effects like myelosuppression, mucositis and
diarrhea. Surgical or percutaneous placement of a subcu-
taneous device allows chemotherapy to be delivered con-
tinuously into the gastroduodenal artery via a catheter.
Regional chemotherapy predominantly for the treatment
of colorectal liver metastases was increasingly used in the
late 1980s and 1990s because of the limited efficacy of
available systemic treatment options [3-9]. This approach
was also evaluated in the treatment of unresectable pri-
mary liver tumors and as adjuvant treatment after metas-
tasectomy [10-14]. However, the application of
floxuridine-deoxy-ribose (FUDR), a prodrug of 5-fluorou-
racil (5-FU) with a high liver extraction fraction, into the
hepatic artery can cause several complications. Biliary tox-
icity is the dose limiting side effect of HAC with FUDR,
usually indicated by an increase of bilirubin and liver
enzymes [15-18]. Other infrequent complications are gas-
tric and duodenal ulcerations, mainly due to misper-
fusion. Rarely thrombosis, nausea, vomiting and diarrhea
occur [16,19,20]. Pocket infections, development of
cholangitis and liver abscesses have also been reported
[21].
A rare complication of HAC is the formation of pseudoan-
eurysms of the hepatic artery. In this article we describe
two patients who developed aneurysmatic cavities of the
hepatic artery after regional chemotherapy with FUDR
and presented with hemorrhage.
Case presentation
Case 1
A 62-year-old male patient presented in May 2001 with
initially unresectable metachronous liver metastases of a
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surgically treated rectal carcinoma. Cholecystectomy and
implantation of an infusion system (Arrow pump, Cod-
man 3000, Johnson & Johnson, Raynham, Mass.) were
carried out by laparotomy. From June 2001 to October
2001 he received four cycles of neoadjuvant HAC with
FUDR monotherapy in a total dose of 1100 mg. In
November 2001 hemihepatectomy of the right lobe could
be performed after downsizing of the metastases. Five
months later, he developed a solitary liver metastasis. In
April 2002 a wedge-resection was performed, followed by
one cycle of adjuvant HAC with FUDR in May 2002. 15
days after restart of regional therapy the patient presented
with abdominal pain. Computed tomography revealed a
large retroperitoneal hematoma and a ruptured pseu-
doaneurysm of the hepatic artery at the site of the catheter
tip.
In a subsequent angiography via a transfemoral access a
stent-graft was placed into the hepatic artery in order to
preserve arterial hepatic perfusion. This led only to a par-
tial exclusion of the aneurysm and was complicated by a
dissection of the hepatic artery, reflecting its friability.
Definitive treatment was finally achieved by coil emboli-
zation (Figures 1, 2). After clinical stabilization, the pump
system was removed. Regional therapy was discontinued
and the patient recovered uneventfully.
Case 2
A 38-year-old female patient was diagnosed with a multi-
focal hepatocellular carcinoma in July 2000. Hemihepate-
ctomy of the right lobe, resection of segment I and
cryosurgery of a satellite lesion in segment II were per-
formed one month later. Because of recurrence of the
tumor, a wedge resection of segment III/IV followed in
February 2001. Concurrently, an Arrow pump system was
implanted in a subcutaneous pocket on the lower right
side of the abdomen. The catheter tip was placed at the
origin of the gastroduodenal artery. From May 2001 to
September 2001 she received HAC with 5 cycles of FUDR
in a total dose of 600 mg to slow down tumor growth
until orthotopic liver transplantation could be performed.
In October 2001 the treatment had to be discontinued
because of biliary toxicity with elevated liver enzymes and
bilirubin. Five months later she had progressive disease
and HAC was started again. Because of the previous toxic-
ity, FUDR was administered in reduced dose. After com-
pletion of the fourth cycle, she presented to our
emergency room with jaundice, fever and epigastric pain
in June 2002. She was hospitalized and antibiotic treat-
ment with ciprofloxacin was started. After isolation of
Klebsiella pneumoniae from the blood culture, antibiotic
treatment was changed to piperacillin and tazobactam.
Percutaneous transhepatic cholangiography showed mul-
tiple liver abscesses. A few days later the patient developed
severe hematemesis and melena necessitating blood
transfusions. Gastroscopy showed blood remnants with-
out any lesions of the gastrointestinal mucosa and hemo-
bilia was seen in a repeated cholangiogram. Finally,
computed tomography revealed a pseudoaneurysm of a
segmental left hepatic artery, about 5 cm from the site of
the catheter tip close to the hepato-enteric anastomosis
(Figure 3). The development of a hepatic artery-biliary fis-
tula was assumed to be the cause of the gastrointestinal
bleeding.
Angiography was performed via a transfemoral access,
and after placement of a 4 French catheter in the segmen-
Celiac angiogram Figure 1
Celiac angiogram. The celiac angiogram shows a pseu-
doaneurysm (arrow) of the proper hepatic artery located 
next to the origin of the gastroduodenal artery, which is 
occluded by the chemotherapy infusion catheter (arrow-
heads). The right hepatic artery is missing after hemihepatec-
tomy.
Completion celiac angiogram Figure 2
Completion celiac angiogram. In the completion celiac 
angiogram the common hepatic artery is occluded by the 
microcoils (arrows). The liver is supplied uniquely by the pat-
ent portal vein.International Seminars in Surgical Oncology 2008, 5:17 http://www.issoonline.com/content/5/1/17
Page 3 of 5
(page number not for citation purposes)
tal artery the aneurysm was occluded by coil embolization
(Figures 4, 5). A few days later, the fever and jaundice
resolved completely. The arrow pump was removed and
no further chemotherapy was applied. The patient recov-
ered uneventfully.
Discussion
Pseudoaneurysms of the hepatic artery due to placement
of a catheter into the gastroduodenal artery and treatment
with continuous regional chemotherapy are described
infrequently in the literature [9,13,22]. They can remain
clinically silent even after continuation of the treatment
[23]. A few case reports describe the development of hem-
orrhage after rupture of the pseudoaneurysm or fistula-
tion to a bile duct or the intestine [24-26].
Pseudoaneurysms usually develop after percutaneous or
surgical procedures as a result of dissection of the vessel.
A penetrating trauma leads to a disruption of the media
without blood seepage through the adventitia. The late
development after multiple courses of intra-arterial chem-
otherapy, as described in our two patients, emphasises the
role of HAC as a potential cause. Hepatic artery aneurysms
account for 20% of all visceral aneurysms [27]. The rate of
rupture was reported to be as high as 65%, with a mortal-
ity rate of 20% [28]. Symptoms of rupture include abdom-
inal pain in case of retroperitoneal bleeding and
hematemesis or melena, if the aneurysm is in contact with
the biliary tract or the duodenal lumen. Early interven-
tional therapy is necessary to control hemorrhage. The
preferred approach is a hepatic angiography with subse-
quent coil embolization because pseudoaneurysms are
usually located adjacent to the hilum of the liver, making
surgery difficult [29-33]. Major risks of this procedure
include arterial dissection, artery occlusion, thromboem-
bolic phenomena and intraprocedural rupture of the
aneurysm. Recently, promising results were reported with
endovascular stent-graft placement, but long-term results
are still lacking [34,35]. There are also reports of success-
ful treatment with computed tomography guided percuta-
neous embolization and ultrasound guided percutaneous
thrombin injection [36,37].
Considering the development and widespread use of
more effective systemic chemotherapy, the use of regional
chemotherapy decreased in the last years. A recent meta-
analysis showed that FUDR-based HAC alone does not
improve response rates and outcome compared with 5-FU
based combination chemotherapy [38]. However, the role
Contrast-enhanced abdominal CT Figure 3
Contrast-enhanced abdominal CT. The left liver lobe is 
hypertrophied after extended right hemihepatectomy. There 
is an arterial pseudoaneurysm (arrow) close to the hepato-
enteric anastomosis. A hypervascular metastasis is depicted 
on the same cut (arrowheads).
Celiac angiogram Figure 4
Celiac angiogram. Celiac angiogram with pseudoaneurysm 
of a left segmental artery (arrow) and disseminated metas-
tases (arrowheads).
Completion hepatic arteriogram Figure 5
Completion hepatic arteriogram. Coils in the segmental 
artery III (arrowheads) after embolisation. Due to hepatic 
redistribution the embolized segmental artery is opacified 
distally to the coils. A hepatic chemotherapy infusion cathe-
ter had been inserted into the gastroduodenal artery (arrow).International Seminars in Surgical Oncology 2008, 5:17 http://www.issoonline.com/content/5/1/17
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of regional chemotherapy with FUDR in primary liver
tumors and in combination with efficient systemic chem-
otherapy in colorectal liver metastases has not been
defined yet. HAC should be utilized only in high-volume
centers with expertise in this field due to the high techni-
cal demands of this procedure, since the rate of complica-
tions is clearly related to the surgeon's experience [39].
Clinicians should be aware of the possibly life threatening
complications in patients treated with HAC. Because of
the unpredictable course of pseudoaneurysms, early treat-
ment with interventional radiological techniques should
be considered. In the case of our two patients, angiogra-
phy with coil embolization was necessary to control the
critical condition.
Conclusion
Hepatic artery pseudoaneurysms may complicate regional
chemotherapy with floxuridine. Prompt angiography
with coil embolization is the preferred treatment to avoid
life threatening hemorrhage in these patients.
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